Lokal İleri Yinelemiş Bazal Hücreli Karsinom Tanılı Bir Olguda Eşzamanlı Vismodegib ve Hipofraksiyone Stereotaktik Radyoterapi: Olgu Sunumu

Yıl 2025, Cilt: 51 Sayı: 2, 325 - 330, 28.08.2025

Oktay Çayırlı , Javad Teimouri , Feride Güler , Süreyya Sarıhan

https://doi.org/10.32708/uutfd.1677759

Öz

Bu çalışmada, vismodegib ve hipofraksiyone stereotaktik radyoterapi (hSRT) kombinasyonu ile tedavi edilmiş olan yüzün yüksek riskli bölgesinde yerleşmiş yinelemiş bazal hücreli karsinom (BHK)’ lu bir hasta sunulmaktadır. Hedgehog yolu inhibitörleri gibi hedeflenmiş tedaviler, ileri evre BHK tedavisinde önemli bir rol oynar, ancak direnç nedeniyle yanıt süresi kısadır. Hedgehog yolak inhibitörleri ve radyoterapinin kombinasyonu, özellikle lokal ileri evre hastalarda kalıcı ve etkili bir tedavi yanıtı sağlama potansiyeline sahiptir. 68 yaşında bir erkek hastada, nazal dorsuma lokalize ve her iki gözün medial kantusuna kadar uzanan, nazal ve maksiller kemikleri infiltre eden nüks kitle mevcuttu. Lezyon kenarlarından alınan çoklu biyopsiler, infiltratif BHK ve bazoskuamöz hücreli karsinom odakları şeklinde raporlanmıştı. Vismodegib’e iyi yanıt veren hastaya cerrahi düşünülmemişti. Risk altındaki organların toleransı göz önüne alınarak CyberKnife-M6 cihazı ile eşzamanlı 4200 santigray/14 fraksiyon hSRT uygulandı. Tedavi sırasında akut derece 1-2 toksisite gözlendi. Tedavi sonunda kitle geriledi, sol gözdeki pitozis azaldı ve görme alanı genişledi. Tedaviden 4 ay sonra radyolojik ve klinik tam yanıt elde edildi. Tekrarlayan lokal ileri evre BHK’lu bir hastada kombine tedavi etkin bulundu. Vismodegib ve hSRT kombinasyonu ileri prospektif çalışmalarla değerlendirilmelidir.

Anahtar Kelimeler

bazal hücreli karsinom , stereotaktik radyoterapi , vismodegib

Concurrent Vismodegib and Hypofractionated Stereotactic Radiotherapy in a Patient with Recurrent Locally Advanced Basal Cell Carcinoma: Case Report

Öz

In this study, we present a patient with recurrent basal cell carcinoma (BCC) located in a high-risk area of the face who was treated with a combination of vismodegib and hypofractionated stereotactic radiotherapy (hSRT). Targeted therapies such as hedgehog pathway inhibitors play an important role in the treatment of advanced BCC, but the duration of response is limited due to resistance. The combination of hedgehog pathway inhibitors and radiotherapy has the potential to achieve a durable and effective therapeutic response, particularly in patients with locally advanced disease. A 68-year-old male patient had a recurrent mass localized to the nasal dorsum and extending to the medial canthus of both eyes, infiltrating the nasal and maxillary bones. Multiple biopsies taken from the lesion edges reported infiltrative BCC and basosquamous cell carcinoma foci. The patient responded well to vismodegib, but surgery was not considered. Considering the tolerance of the organs at risk, concurrent 4200 centigray/14 fractions hSRT was applied with the CyberKnife-M6 device. Acute grade 1 to 2 toxicity was observed during treatment. At the end of treatment, the mass regressed, ptosis in the left eye decreased, and the visual field expanded. Complete radiological and clinical response was achieved four months after treatment. Combination therapy was found to be effective in a patient with recurrent locally advanced BCC. The combination of vismodegib and hSRT should be evaluated in prospective studies.

Anahtar Kelimeler

basal cell carcinoma , stereotactic radiotherapy , vismodegib

Kaynakça

• 1. Nagarajan P, Asgari MM, Green AC, Guhan SM, Arron ST, Proby CM, et al. Keratinocyte carcinomas: current concepts and future research priorities. Clin Cancer Res. 2019; 25(8):2379.
• 2. Aggarwal P, Knabel P, Fleischer AB, Jr. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J. Am Acad Dermatol. 2021, 85: 388–395.
• 3. Amini A, Freeman M, Melstrom L, Margolin KA, Parekh V, Abdulla FR, et al. Pathologic complete response with radiation and vismodegib in a patient with advanced basal cell carcinoma: A case report. Mol Clin Oncol. 2021, 14(3): 46.
• 4. Bonilla X, Parmentier L, King B, bezrukov F, Kaya G, Zoete V, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet, 2016, 48(4): 398-406.
• 5. Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J. Am Acad Dermatol. 2015; 72(6):1021.
• 6. Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716-728.
• 7. Hehlgans S, Booms P, Gullulu O, Sader R, Rodel C, Balermpas P, et al. Radiation sensitization of basal cell and head and neck squamous cell carcinoma by the hedgehog pathway inhibitor vismodegib. Int J Mol Sci. 2018; 19:2485.
• 8. Gathings RM, Orscheln CS, Huang WW. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin. J Am Acad Dermatol. 2014, 70(4):e88-e89.
• 9. Pollom EL, Bui TT, Chang AL, Colevas AD, Hara WY. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma. JAMA Dermatol. 2015, 151(9): 998-1001.
• 10. Block AM, Alite F, Diaz AZ, Borrowdale RW, Clarck JI, Choi M. Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face. Case Rep Oncol Med. 2015; 827608.
• 11. Barker CA, Dufault S, Arron ST, Lo AL, Algazi AP, Dunn LA, et al. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma. J Clin Oncol. 2024; 42(19):2327-2335.
• 12. Zaorsky NG, Lee CT, Zhang E, Keith SW, Galloway TJ. Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis. Radiother Oncol. 2017; 125:13-20.
• 13. Pontoriero A, Iatì G, Conti A, Minutoli F, Bottari A, Pergolizzi S, et al. Treatment of periocular basal cell carcinoma using an advanced stereotactic device. Anticancer Res. 2014, 34(2): 873-5.
• 14. Suzuki S, Yasukawa S, Tsuchimochi T, Inoue T. Gamma knife radiosurgery for basal cell carcinoma of the eyelid: report of a case. Acta Neurochir,2018, 160: 357-359.
• 15. Schüler E, Lo A, Chuang CF, Soltys SG, Pollom EL; Wang L. Clinical impact of the VOLO optimizer on treatment plan quality and clinical treatment efficiency for CyberKnife. J Appl Clin Med Phys, 2020, 21 (5): 38-47.
• 16. Avril MF, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997, 76:100-106.
• 17. Drucker AM, Adam GP, Rofeberg V, Gazula A, Smith B, Moustafa F, et al. Treatments of primary basal cell carcinoma of the skin: A systematic review and network meta-analysis. Ann Inter Med. 2018, 169(7): 456-466.
• 18. Hennequin C, Rio E, Quero L, Clavere P. Radiation therapy of cutaneous cancers. Cancer Radiother. 2022, 26: 397-403.
• 19. Iuliano A, Strianese D, Uccello G, Diplomatico A, Teballi S, Bonavolonta G. Risk factors for orbital exenteration in periocular basal cell carcinoma. Am J Ophthalmol. 2012, 153(2): 238- 241.
• 20. van Hezewijk M, Creutzberg CL, Putter H, Chin A, Schneider I, Hoogeveen M, et al. Efficacy of a hypofractionated schedule in elecron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. Radiother Oncol. 2010, 95(2): 245-9.
• 21. Locke J, Karimpour S, Young G, Lockett MA, Perez CA. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol, Phys. 2001;51(3):748-755.
• 22. Silva JJ, Tsang RW, Panzarella T, Levin W, Wells W. Results of radiotherapy for epithelial skin cancer of the pinna: the Princess Margaret Hospital experience, 1982-1993. Int J Radiat Oncol Biol Phys. 2000; 47(2):451-459.
• 23. Weissman JP, Samlowski W, Meoz R. Hedgehog Inhibitor Induction with Addition of Concurrent Superficial Radiotherapy in Patients with Locally Advanced Basal Cell Carcinoma: A Case Series. Oncologist. 2021, 26(12):e2247-e2253.
• 24. Likhacheva A, Awan M, Barker CA, Bhatnagar A, Bradfield L, Brady MS, et al. Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: Executive summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol. 2020, 10(1): 8-20.
• 25. Timmerman R. A story of hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys. 2022, 112(1): 4-21.